Medical costs and associated racial/ethnic and sex disparities in erythropoiesis-stimulating agent use: anemia management under the Medicare reimbursement policy

BACKGROUND: Before 2007, erythropoiesis-stimulating agents (ESAs) were the highest-expenditure drug in the Medicare system. In 2007, CMS issued a reimbursement policy change for ESAs used by cancer patients. However, empirical evidence is currently lacking to evaluate medical costs after the policy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Minghui, Cai, Bo, Mauldin, Patrick, Lu, Z Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391219/
https://www.ncbi.nlm.nih.gov/pubmed/34337992
http://dx.doi.org/10.18553/jmcp.2021.27.8.1142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391219/
https://www.ncbi.nlm.nih.gov/pubmed/34337992
http://dx.doi.org/10.18553/jmcp.2021.27.8.1142

Ejemplares similares